VivoSeq
Oncology

Urothelial Cancer

15

Pipeline Programs↗

25

Active Trials↗

18

Companies Involved↗

Urothelial Cancer is an emerging landscape with 15 programs across 18 companies. The most active players are EMD Serono, Johnson & Johnson, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.. 9 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

30/100

Mech. Concentration

22/100

Completion Rate

67/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

EMD Serono logo

EMD Serono

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

2 programs

Phase 3M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 3G

Gynecologic Oncology Group

1 program

Phase 3Merck & Co. logo

Merck & Co.

1 program

Phase 3Pfizer logo

Pfizer

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

86%

Small molecule

12 of 14 classified programs — the dominant modality here.

14%ALL OTHERSMonoclonal antibody17%Antibody–drug conjugate17%

Small molecule leads; the ring shows all 14 classified programs, each share of the total. Modality classified for 100% of 15 pipeline programs.

Analysis

Trial Status

64

clinical trials

Completed24 · 38%
Recruiting17 · 27%
Terminated8 · 13%
Active, not recruiting8 · 13%
Withdrawn4 · 6%
Unknown status3 · 5%

Clinical Trials

Trial Activity

64 trials

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer
Recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT05775471·21 enrolled
A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
Recruiting·Astellas logoAstellas·Phase 4·NCT06862219·100 enrolled
9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
Recruiting·MMabwell (Shanghai) Bioscience Co., Ltd.·Phase 2·NCT07314723·90 enrolled
Renal Retention in High Grade Upper Tract Urothelial Cancer
Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT05656235·20 enrolled
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Recruiting·UUroGen Pharma Ltd.·N/A·NCT05874921·400 enrolled
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT06237920·90 enrolled
Circulating Tumor DNA Response In Urothelial Cancer
Recruiting·UUniversity of Oklahoma·Phase 2·NCT07183319·30 enrolled
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
Recruiting·SSteba Biotech S.A.·Phase 3·NCT04620239·100 enrolled
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Recruiting·Gilead logoGilead·Phase 2·NCT03547973·827 enrolled
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Recruiting·UUroGen Pharma Ltd.·Phase 3·NCT06774131·70 enrolled
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Recruiting·Pfizer logoPfizer·Phase 2·NCT04879329·372 enrolled
AN INTERVENTIONAL PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, ANTITUMOR ACTIVITY, AND PHARMACOKINETICS OF PF 08634404 MONOTHERAPY OR IN COMBINATION WITH ENFORTUMAB VEDOTIN IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER
Recruiting·Pfizer logoPfizer·Preclinical·NCT07421700·132 enrolled
Use-result Surveillance for PADCEV Injection 20 mg and 30 mg (Enfortumab Vedotin) in South Korea
Recruiting·Astellas logoAstellas·N/A·NCT06011954·202 enrolled
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Recruiting·National Cancer Institute (NCI)·N/A·NCT04923178·1,100 enrolled
IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Preclinical·NCT07106762·470 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)